Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

被引:57
|
作者
Horneff, Gerd [1 ]
Klein, Ariane [1 ]
Klotsche, Jens [2 ,3 ]
Minden, Kirsten [2 ,3 ]
Huppertz, Hans-Iko [4 ]
Weller-Heinemann, Frank [4 ]
Kuemmerle-Deschner, Jasmin [5 ]
Haas, Johannes-Peter [6 ]
Hospach, Anton [7 ]
机构
[1] Asklepios Clin Sankt Augustin, Ctr Gen Pediat & Neonatol, Dept Pediat, D-53757 St Augustin, Germany
[2] German Rheumatism Res Ctr Berlin, Berlin, Germany
[3] Childrens Univ Hosp Charite, Berlin, Germany
[4] Prof Hess Childrens Hosp, Bremen, Germany
[5] Univ Tubingen, Dept Pediat, D-72076 Tubingen, Germany
[6] German Ctr Pediat & Adolescent Rheumatol, Garmisch Partenkirchen, Germany
[7] Olgahospital, Klinikum, Rheumatol Sect, Dept Pediat, Stuttgart, Germany
关键词
Adalimumab; Etanercept; Tocilizumab; Juvenile idiopathic arthritis; Drug surveillance; JADAS; PLACEBO-CONTROLLED TRIAL; DISEASE-ACTIVITY SCORE; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; PEDIATRIC RHEUMATOLOGY; JIA REGISTRY; SAFETY; METHOTREXATE; BIOLOGICS; CHILDREN;
D O I
10.1186/s13075-016-1170-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. Methods: Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival were compared. Results: Two hundred thirty-six patient started adalimumab, 419 etanercept and 74 tocilizumab, with differences in baseline patient characteristics. Baseline Juvenile Disease Activity Score (JADAS) 10 (mean +/- SD) in the adalimumab/etanercept/tocilizumab cohorts was 12.1+/-7.6, 13.8 +/- 7.1 and 15.1 +/- 7.4, respectively (adalimumab vs etanercept, p = 0.01), and Childhood Health Assessment Questionnaire (CHAQ)-disability index scores was 0.43 +/- 0.58, 0.59 +/- 0.6 and 0.63 +/- 0.55, respectively (adalimumab vs etanercept, p < 0.001). Uveitis history was more frequent in the adalimumab cohort (OR 5.73; p < 0.001). Balanced patients' samples were obtained by a generalized propensity score to adjust for baseline differences. Pediatric ACR30/50/70/90 criterion improvement after 3 months treatment was achieved by 68%/60%/42%/24% in the etanercept cohort, 67%/59%/43%/27% in the adalimumab cohort and 61%/52%/35%/26% in the tocilizumab cohort. At 24 months, JADAS minimal disease activity was achieved in 52. 4%/61.3%/52.4% and JADAS remission in 27.9%/34.8%/27.9% patients in the adalimumab/etanercept/tocilizumab cohorts, respectively. Etanercept was used in 95.5% of patients as a first biologic, adalimumab in 50.8% and tocilizumab in 20.2%. There were no important differences in efficacy between first-line and second-line use of biologics. In total 60.4%/49.4%/31.1% patients discontinued adalimumab/etanercept/tocilizumab, respectively (HR for adalimumab 1.67; p < 0.001; HR for tocilizumab 0.35; p = 0.001). Drug survival rates did not differ significantly in patients on biologic monotherapy compared with combination therapy with methotrexate. Over 4 years observation under etanercept/adalimumab/tocilizumab, 996/386/103 adverse events, and 148/119/26 serious adverse events, respectively, were reported. Conclusions: In clinical practice, etanercept is most frequently used as first-line biologic. Adalimumab/etanercept/tocilizumab showed comparable efficacy toward polyJIA. Overall, tolerance was acceptable. Interestingly, compliance was highest with tocilizumab and lowest with adalimumab. This study provides the first indication for the comparison of different biologic agents in polyarticular JIA based on observational study data with all their weaknesses and demonstrates the need for well-controlled head-to-head studies for confirmation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
    Horneff, Gerd
    Klein, Ariane
    Minden, Kirsten
    Huppertz, Hans-Iko
    Weller-Heinemann, Frank
    Kuemmerle-Deschner, Jasmin B.
    Haas, Johannes Peter
    Hospach, Toni
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
    Gerd Horneff
    Ariane Klein
    Jens Klotsche
    Kirsten Minden
    Hans-Iko Huppertz
    Frank Weller-Heinemann
    Jasmin Kuemmerle-Deschner
    Johannes-Peter Haas
    Anton Hospach
    [J]. Arthritis Research & Therapy, 18
  • [3] THE EFFICACY AND SAFETY OF ABATACEPT, ADALIMUMAB, ETANERCEPT AND TOCILIZUMAB ARE COMPARABLE IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
    Kathi, H.
    Pennington, B.
    Amadi, A.
    Lister, S.
    Nanuwa, K.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A636 - A636
  • [4] Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
    OU Loskutova (Konopelko)
    ES Zholobova
    MN Nikolaeva
    LA Galstian
    [J]. Pediatric Rheumatology, 12 (Suppl 1)
  • [5] Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis
    Geikowski, Tilman
    Becker, Ingrid
    Horneff, Gerd
    [J]. RHEUMATOLOGY, 2014, 53 (07) : 1245 - 1249
  • [6] CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS FOLLOWING TREATMENT WITH ADALIMUMAB
    Kingsbury, D.
    Quartier, P.
    Horneff, G.
    Minden, K.
    Toth, M.
    Varothai, N.
    Cardoso, A.
    Kalabic, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 382 - 382
  • [7] Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab
    Kingsbury, Daniel J.
    Quartier, Pierre
    Horneff, G.
    Minden, Kirsten
    Toth, Mary
    Varothai, Nupun A.
    Cardoso, Anabela
    Kalabic, Jasmina
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
    Brunner, Hermine I.
    Ruperto, Nicola
    Nanda, Kabita
    Toth, Mary
    Foeldvari, Ivan
    Bohnsack, John F.
    Milojevic, Diana
    Rabinovich, C. Egla
    Kingsbury, Daniel J.
    Marzan, Katherine
    Quartier, Pierre
    Minden, Kirsten
    Chalom, Elizabeth
    Horneff, Gerd
    Kuester, Rolf M.
    Dare, Jason A.
    Bereswill, Mareike
    Kalabic, Jasmina
    Kupper, Hartmut
    Lovell, Daniel J.
    Martini, Alberto
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
    Lovell, Daniel J.
    Ruperto, Nicola
    Wallace, Carol
    Toth, Mary
    Foeldvari, Ivan
    Bohnsack, John
    Milojevic, Diana
    Rabinovich, C. Egla
    Kingsbury, Daniel
    Marzan, Katherine
    Quartier, Pierre
    Minden, Kirsten
    Chalom, Elizabeth
    Horneff, Gerd
    Kuester, Rolf M.
    Dare, Jason
    Heinrich, Miriam
    Kupper, Hartmut
    Kalabic, Jasmina
    Brunner, Hermine I.
    Martini, Alberto
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept
    Otten, Marieke H.
    Prince, Femke H. M.
    Twilt, Marinka
    van Rossum, Marion A. J.
    Armbrust, Wineke
    Hoppenreijs, Esther P. A. H.
    Kamphuis, Sylvia
    Koopman-Keemink, Yvonne
    Wulffraat, Nico M.
    Gorter, Simone L.
    ten Cate, Rebecca
    van Suijlekom-Smit, Lisette W. A.
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (03) : 665 - 667